Lymphoma Antibody Drug Conjugates Market Clinical Trials Insight 2030, by Company, Country, Indication and Phase [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
These show promise due to their ability to precisely deliver cytotoxic drugs to cancer cells while sparing healthy tissue. Increased clinical trials and technological advancements bolster market potential. Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Lymphoma, a form of blood cancer of the lymphatic system, is still a major concern in cancer therapy because of its nature and heterogeneity. Although chemotherapy and immunotherapy have been extensively applied, numerous patients, particularly those with relapsed or refractory lymphoma, resist these therapies. This has driven the demand for more focused therapies, including antibody drug conjugates. These antibody drug conjugates are a promising option by targeting cytotoxic drugs to deliver to cancer cells via monoclonal antibodies, minimizing harm to h
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]Seeking Alpha
- ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! FinanceYahoo! Finance
- ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaPR Newswire
ADCT
Earnings
- 11/10/25 - Beat
ADCT
Sec Filings
- 12/5/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form S-3
- ADCT's page on the SEC website